Last reviewed · How we verify
Treatment plan
Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells.
Rituximab is a monoclonal antibody that targets and depletes CD20-positive B cells. Used for Non-Hodgkin's lymphoma, Chronic lymphocytic leukemia, Rheumatoid arthritis.
At a glance
| Generic name | Treatment plan |
|---|---|
| Sponsor | Fondazione Italiana Linfomi - ETS |
| Drug class | Monoclonal antibody |
| Target | CD20 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Rituximab works by binding to the CD20 antigen on the surface of B cells, leading to their depletion through mechanisms such as complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. This results in a reduction in B cell-mediated inflammation and immune responses. Rituximab is often used in combination with other therapies to achieve optimal treatment outcomes.
Approved indications
- Non-Hodgkin's lymphoma
- Chronic lymphocytic leukemia
- Rheumatoid arthritis
Common side effects
- Infusion reactions
- Infections
- Neutropenia
Key clinical trials
- Study of a Support Program for Quality of Life in Chinese Cancer Patients and Survivors (NA)
- BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- Effect of Scalp Block on Intraoperative Hemodynamics and Postoperative Pain in Craniotomy Patients" (NA)
- Individualised Endometrial Cancer Risk Stratification by Bayesian Prediction Model (ENDORISK), Optimizing Clinical Implementation (NA)
- The Effect of the DASH Diet on Treatment Outcomes in Adults Diagnosed With Rheumatoid Arthritis (NA)
- Early Surgical Intervention of Congenital Hemivertebra in Young Children (NA)
- Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis (PHASE1)
- Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Treatment plan CI brief — competitive landscape report
- Treatment plan updates RSS · CI watch RSS
- Fondazione Italiana Linfomi - ETS portfolio CI